DGIdb - MS4A1 Gene Record

MS4A1 931 Druggable Genome

Alternate Names:

931
MEMBRANE SPANNING 4-DOMAINS A1
MS4A1
B1
Bp35
CD20
CVID5
LEU-16
MS4A2
S7
112210
7315
ENSG00000156738
OTTHUMG00000167614
CD_antigen=CD20
Leukocyte surface antigen Leu-16
B-lymphocyte surface antigen B1
B-lymphocyte antigen CD20
Membrane-spanning 4-domains subfamily A member 1
P11836
CD20_HUMAN
BE0000066
2628
CD20 (membrane-spanning 4-domains, subfamily A, member 1)
PA31111
T73215
NM_152866
NP_690605

Gene Info:

Target Subclass	Unknown_function
Target Main Class	Other
Target Subclass	MS4A
Transmembrane Helix Count	4
Target Class	Other
Target Class	Miscellaneous
Target Subclass	MS4A family
Gene Biotype	PROTEIN_CODING
GuideToPharmacology Gene Category Name	CD molecules
GuideToPharmacology Gene Category ID	852

(10 More Sources)

Gene Categories: Category Details

CELL SURFACE
EXTERNAL SIDE OF PLASMA MEMBRANE
DRUGGABLE GENOME

Publications:

McLaughlin P et al., 1998, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program., J Clin Oncol
van Meerten et al., 2010, CD20-targeted therapy: the next generation of antibodies., Semin. Hematol.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Jaglowski et al., 2010, Rituximab in chronic lymphocytic leukemia., Semin. Hematol.
Goldenberg, The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy., Crit. Rev. Oncol. Hematol.
Friedberg et al., 2004, Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma., Expert Rev Anticancer Ther
Dillman, Monoclonal antibody therapy for lymphoma: an update., Cancer Pract
2003, Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab., BioDrugs
Silverman et al., 2004, Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues., Cancer Treat. Rev.
Beeson et al., Conditionally cleavable radioimmunoconjugates: a novel approach for the release of radioisotopes from radioimmunoconjugates., Bioconjug. Chem.
Du et al., 2009, Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20., Mol. Immunol.
Dörner et al., 2008, New approaches of B-cell-directed therapy: beyond rituximab., Curr Opin Rheumatol
Glennie et al., 2007, Mechanisms of killing by anti-CD20 monoclonal antibodies., Mol. Immunol.
Robak, 2009, GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies., Curr Opin Investig Drugs
Terszowski G et al., 2014, KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity., J Immunol
Reddy V et al., 2016, Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?, Drug Discov Today
McGinley MP et al., 2017, Safety of monoclonal antibodies for the treatment of multiple sclerosis., Expert Opin Drug Saf

OFATUMUMAB MS4A1

Interaction Score: 31.56

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name HuMax-CD20

Novel drug target Established target

Details of the Assay for Interaction Binding affinity for clone 2F2 ((HuMax-CD20).

PMIDs:
19427037 18388516 17768100

Sources:
PharmGKB TdgClinicalTrial TTD DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions
OBINUTUZUMAB MS4A1

Interaction Score: 28.4

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction B-lymphocyte antigen CD20 inhibitor

Direct Interaction yes

Trial Name afutuzumab, R-7159, GA-101

PMIDs:
19513948 24795454

Sources:
FDA PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions
OCRELIZUMAB MS4A1

Interaction Score: 22.09

Interaction Types & Directionality:

antibody (inhibitory)

antagonist (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Binding

PMIDs:
27343722 27756172

Sources:
TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions
TOSITUMOMAB MS4A1

Interaction Score: 22.09

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name tositumomab,Bexxar

Novel drug target Established target

Mechanism of Interaction B-lymphocyte antigen CD20 inhibitor

PMIDs:
11418316 14748653 11879282 12899647 11752352 15023434 13129395

Sources:
TEND PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions
IBRITUMOMAB TIUXETAN MS4A1

Interaction Score: 12.62

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
None found

Sources:
TEND PharmGKB TdgClinicalTrial TTD
VELTUZUMAB MS4A1

Interaction Score: 9.47

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction B-lymphocyte antigen CD20 inhibitor

Specific Action of the Ligand Binding

PMIDs:
None found

Sources:
TTD GuideToPharmacology ChemblInteractions
UBLITUXIMAB MS4A1

Interaction Score: 9.47

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

Specific Action of the Ligand Binding

Endogenous Drug? False

Direct Interaction? True

PMIDs:
None found

Sources:
TTD GuideToPharmacology ChemblInteractions
LFB-R603 MS4A1

Interaction Score: 3.16

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name LFB-R603

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
YTTRIUM Y 90 IBRITUMOMAB TIUXETAN MS4A1

Interaction Score: 3.16

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction B-lymphocyte antigen CD20 binding agent

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
TRU-015 MS4A1

Interaction Score: 3.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
FBT-A05 MS4A1

Interaction Score: 3.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
ZEVALIN MS4A1

Interaction Score: 3.16

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome
PLAMOTAMAB MS4A1

Interaction Score: 3.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
MOSUNETUZUMAB MS4A1

Interaction Score: 3.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
ODRONEXTAMAB MS4A1

Interaction Score: 3.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
RITUXIMAB MS4A1

Interaction Score: 2.93

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction B-lymphocyte antigen CD20 inhibitor

Direct Interaction yes

Specific Action of the Ligand Binding

PMIDs:
9704735 20350667 11752352 20350663

Sources:
TEND FDA PharmGKB TdgClinicalTrial TTD DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions
TISAGENLECLEUCEL MS4A1

Interaction Score: 1.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
AME-133V MS4A1

Interaction Score: 1.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD

Ensembl: ENSG00000156738
- Version: 101_38
Alternate Names:

MS4A1 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TdgClinicalTrial: P11836
- Version: January-2014
Alternate Names:

MS4A1 Gene Symbol

Gene Info:

Target Class Miscellaneous

Target Subclass MS4A family

Target Class Other

Publications:
TEND: P11836
- Version: 01-August-2011
Alternate Names:

P11836 Uniprot Accession

MS4A1 Gene Symbol

CD20_HUMAN Uniprot Id

Gene Info:

Target Subclass Unknown_function

Target Main Class Other

Target Subclass MS4A

Publications:
GuideToPharmacology: 931
- Version: 29-September-2020
Alternate Names:

7315 HUGO Gene ID

7315 HUGO Gene Symbol

membrane spanning 4-domains A1 HUGO Gene Name

Gene Info:

GuideToPharmacology Gene Category Name CD molecules

GuideToPharmacology Gene Category ID 852

Publications:
PharmGKB: MS4A1
- Version: 18-August-2020
Alternate Names:

PA31111 PharmGKB ID

Gene Info:

Publications:

Terszowski G et al., 2014, KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity., J Immunol

DrugBank: BE0000066

Version: 5.1.7

Alternate Names:

MS4A1 DrugBank Gene Name

P11836 UniProt Accession

931 Entrez Gene Id

Gene Info:

Publications:

Goldenberg, The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy., Crit. Rev. Oncol. Hematol.

Witzig, 2004, Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma., Drugs Today

Dillman, Monoclonal antibody therapy for lymphoma: an update., Cancer Pract

TTD: Leukocyte surface antigen Leu-16

Version: 2020.06.01

Alternate Names:

CD20 TTD Gene Abbreviation

T73215 TTD Target ID

Gene Info:

Publications:

Levesque MC, 2009, Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders., Clin Exp Immunol

Lum LG et al., 2013, CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma., Biol Blood Marrow Transplant

NCI: MS4A1
- Version: 14-September-2017
Alternate Names:

Gene Info:

Publications:

Valentine et al., 1987, Expression of the human B-cell surface protein CD20: alteration by phorbol 12-myristate 13-acetate., Proc. Natl. Acad. Sci. U.S.A.
MyCancerGenome: MS4A1
- Version: 20-Jun-2017
Alternate Names:

931 Entrez Gene Id

MS4A1 MyCancerGenome Gene Symbol

CD20 MyCancerGenome Reported Gene Name

Gene Info:

Publications:
ChemblInteractions: CD20
- Version: chembl_23
Alternate Names:

CD20 GENE_SYMBOL

MS4A1 GENE_SYMBOL

B-lymphocyte antigen CD20 UNIPROT

Gene Info:

Publications:
HingoraniCasas: ENSG00000156738
- Version: 31-May-2017
Alternate Names:

ENSG00000156738 Gene Symbol

MS4A1 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
GO: MS4A1
- Version: 05-September-2020
Alternate Names:

CD20 GO Gene Synonym

Gene Info:

Gene Categories:

CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE

Publications:
Tempus: MS4A1
- Version: 11-November-2018
Alternate Names:

MS4A1 Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
FDA: MS4A1
- Version: 04-September-2020
Alternate Names:

Gene Info:

Publications:

Trial Name	HuMax-CD20
Novel drug target	Established target
Details of the Assay for Interaction	Binding affinity for clone 2F2 ((HuMax-CD20).

Mechanism of Interaction	B-lymphocyte antigen CD20 inhibitor
Direct Interaction	yes
Trial Name	afutuzumab, R-7159, GA-101

Direct Interaction?	True
Endogenous Drug?	False
Specific Action of the Ligand	Binding

Trial Name	tositumomab,Bexxar
Novel drug target	Established target
Mechanism of Interaction	B-lymphocyte antigen CD20 inhibitor

Mechanism of Interaction	B-lymphocyte antigen CD20 binding agent
Direct Interaction	yes

7315	HUGO Gene ID
7315	HUGO Gene Symbol
membrane spanning 4-domains A1	HUGO Gene Name

MS4A1	DrugBank Gene Name
P11836	UniProt Accession
931	Entrez Gene Id

931	Entrez Gene Id
MS4A1	MyCancerGenome Gene Symbol
CD20	MyCancerGenome Reported Gene Name

CD20	GENE_SYMBOL
MS4A1	GENE_SYMBOL
B-lymphocyte antigen CD20	UNIPROT

antibody (inhibitory)
inhibitor (inhibitory)

antibody (inhibitory)
inhibitor (inhibitory)

antibody (inhibitory)
antagonist (inhibitory)

antibody (inhibitory)
inhibitor (inhibitory)

MS4A1 Gene Record

MS4A1 931 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Trial Name HuMax-CD20 Novel drug target Established target Details of the Assay for Interaction Binding affinity for clone 2F2 ((HuMax-CD20).

PMIDs: 19427037 18388516 17768100

Sources: PharmGKB TdgClinicalTrial TTD DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction B-lymphocyte antigen CD20 inhibitor Direct Interaction yes Trial Name afutuzumab, R-7159, GA-101

PMIDs: 19513948 24795454

Sources: FDA PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: antibody (inhibitory) antagonist (inhibitory)

Interaction Info: Direct Interaction? True Endogenous Drug? False Specific Action of the Ligand Binding

PMIDs: 27343722 27756172

Sources: TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Trial Name tositumomab,Bexxar Novel drug target Established target Mechanism of Interaction B-lymphocyte antigen CD20 inhibitor

PMIDs: 11418316 14748653 11879282 12899647 11752352 15023434 13129395

Sources: TEND PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: None found

Sources: TEND PharmGKB TdgClinicalTrial TTD

Interaction Types & Directionality: antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction B-lymphocyte antigen CD20 inhibitor Specific Action of the Ligand Binding

PMIDs: None found

Sources: TTD GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: antibody (inhibitory)

Interaction Info: Specific Action of the Ligand Binding Endogenous Drug? False Direct Interaction? True

PMIDs: None found

Sources: TTD GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info: Trial Name LFB-R603 Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Mechanism of Interaction B-lymphocyte antigen CD20 binding agent Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: antibody (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction B-lymphocyte antigen CD20 inhibitor Direct Interaction yes Specific Action of the Ligand Binding

PMIDs: 9704735 20350667 11752352 20350663

Sources: TEND FDA PharmGKB TdgClinicalTrial TTD DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Ensembl: ENSG00000156738

Alternate Names: MS4A1 Ensembl Gene Name

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name HuMax-CD20

Novel drug target Established target

Details of the Assay for Interaction Binding affinity for clone 2F2 ((HuMax-CD20).

PMIDs:
19427037 18388516 17768100

Sources:
PharmGKB TdgClinicalTrial TTD DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction B-lymphocyte antigen CD20 inhibitor

Direct Interaction yes

Trial Name afutuzumab, R-7159, GA-101

PMIDs:
19513948 24795454

Sources:
FDA PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

antibody (inhibitory)

antagonist (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Binding

PMIDs:
27343722 27756172

Sources:
TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name tositumomab,Bexxar

Novel drug target Established target

Mechanism of Interaction B-lymphocyte antigen CD20 inhibitor

PMIDs:
11418316 14748653 11879282 12899647 11752352 15023434 13129395

Sources:
TEND PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
None found

Sources:
TEND PharmGKB TdgClinicalTrial TTD

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction B-lymphocyte antigen CD20 inhibitor

Specific Action of the Ligand Binding

PMIDs:
None found

Sources:
TTD GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

Specific Action of the Ligand Binding

Endogenous Drug? False

Direct Interaction? True

PMIDs:
None found

Sources:
TTD GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name LFB-R603

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction B-lymphocyte antigen CD20 binding agent

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

antibody (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction B-lymphocyte antigen CD20 inhibitor

Direct Interaction yes

Specific Action of the Ligand Binding

PMIDs:
9704735 20350667 11752352 20350663

Sources:
TEND FDA PharmGKB TdgClinicalTrial TTD DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Alternate Names:

MS4A1 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Alternate Names:

MS4A1 Gene Symbol

Gene Info:

Target Class Miscellaneous

Target Subclass MS4A family

Target Class Other

Alternate Names:

P11836 Uniprot Accession

MS4A1 Gene Symbol

CD20_HUMAN Uniprot Id

Gene Info:

Target Subclass Unknown_function

Target Main Class Other

Target Subclass MS4A

Alternate Names:

7315 HUGO Gene ID

7315 HUGO Gene Symbol

membrane spanning 4-domains A1 HUGO Gene Name

Gene Info:

GuideToPharmacology Gene Category Name CD molecules

GuideToPharmacology Gene Category ID 852

Alternate Names:

PA31111 PharmGKB ID

Publications:

Terszowski G et al., 2014, KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity., J Immunol

Alternate Names:

MS4A1 DrugBank Gene Name

P11836 UniProt Accession

931 Entrez Gene Id

Alternate Names:

CD20 TTD Gene Abbreviation

T73215 TTD Target ID

Publications:

Valentine et al., 1987, Expression of the human B-cell surface protein CD20: alteration by phorbol 12-myristate 13-acetate., Proc. Natl. Acad. Sci. U.S.A.

Alternate Names:

931 Entrez Gene Id

MS4A1 MyCancerGenome Gene Symbol

CD20 MyCancerGenome Reported Gene Name

Alternate Names:

CD20 GENE_SYMBOL

MS4A1 GENE_SYMBOL

B-lymphocyte antigen CD20 UNIPROT

Alternate Names:

ENSG00000156738 Gene Symbol

MS4A1 Ensembl Id